Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Merck
Teva
Julphar
US Department of Justice
Fish and Richardson
Novartis
Fuji
Baxter
Boehringer Ingelheim

Generated: October 19, 2017

DrugPatentWatch Database Preview

ENVARSUS XR Drug Profile

« Back to Dashboard

What is the patent landscape for Envarsus Xr, and what generic Envarsus Xr alternatives are available?

Envarsus Xr is a drug marketed by Veloxis Pharms Inc and is included in one NDA. There are thirteen patents protecting this drug.

This drug has fifty-nine patent family members in twenty-four countries.

The generic ingredient in ENVARSUS XR is tacrolimus. There are twenty drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the tacrolimus profile page.

Summary for Tradename: ENVARSUS XR

US Patents:13
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list54
Clinical Trials: see list12
Patent Applications: see list9,870
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ENVARSUS XR at DailyMed

Pharmacology for Tradename: ENVARSUS XR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Veloxis Pharms Inc
ENVARSUS XR
tacrolimus
TABLET, EXTENDED RELEASE;ORAL206406-003Jul 10, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Veloxis Pharms Inc
ENVARSUS XR
tacrolimus
TABLET, EXTENDED RELEASE;ORAL206406-003Jul 10, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Veloxis Pharms Inc
ENVARSUS XR
tacrolimus
TABLET, EXTENDED RELEASE;ORAL206406-002Jul 10, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Veloxis Pharms Inc
ENVARSUS XR
tacrolimus
TABLET, EXTENDED RELEASE;ORAL206406-003Jul 10, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Veloxis Pharms Inc
ENVARSUS XR
tacrolimus
TABLET, EXTENDED RELEASE;ORAL206406-003Jul 10, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Veloxis Pharms Inc
ENVARSUS XR
tacrolimus
TABLET, EXTENDED RELEASE;ORAL206406-001Jul 10, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Veloxis Pharms Inc
ENVARSUS XR
tacrolimus
TABLET, EXTENDED RELEASE;ORAL206406-002Jul 10, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Veloxis Pharms Inc
ENVARSUS XR
tacrolimus
TABLET, EXTENDED RELEASE;ORAL206406-002Jul 10, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Veloxis Pharms Inc
ENVARSUS XR
tacrolimus
TABLET, EXTENDED RELEASE;ORAL206406-003Jul 10, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Veloxis Pharms Inc
ENVARSUS XR
tacrolimus
TABLET, EXTENDED RELEASE;ORAL206406-001Jul 10, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ENVARSUS XR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,014,038,998► Subscribe
9,757,362Modified release compositions comprising tacrolimus► Subscribe
9,763,920Solid dispersions comprising tacrolimus► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ENVARSUS XR

Country Document Number Estimated Expiration
European Patent Office1663216► Subscribe
Japan4996249► Subscribe
Denmark1663216► Subscribe
Hong Kong1096032► Subscribe
TaiwanI510238► Subscribe
Australia2004267909► Subscribe
Canada2537041► Subscribe
Slovenia1663217► Subscribe
Spain2591352► Subscribe
Japan4903568► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Harvard Business School
AstraZeneca
McKinsey
Teva
Chubb
Cipla
Chinese Patent Office
Novartis
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot